Germany-based biopharmaceutical company Affimed Therapeutics, which counts healthcare company Novo Nordisk among its investors, has filed for a $75m initial public offering on Nasdaq.
Founded in 2000, Affimed is developing cancer treatments that would direct the immune system to eliminate tumour cells. It intends to use the IPO proceeds to support research and development costs related to three of its product candidates.
Apart from Novo Nordisk, the company’s shareholders include investment office Aeris Capital, healthcare investment firms Life Sciences Partners and Orbimed, venture capital fund BioMed Invest, though the IPO filing did not reveal the size of their individual stakes.
Although details of its series A round are not publicly available, Affimed raised €65.5m ($89.5m) across three subsequent rounds from 2008 to 2012.
Jefferies, Leerink Partners and BMO Capital Markets are the joint book-running managers for the offering, while Trout Capital is serving as co-manager.